Barclays Raises its Price Target on Jazz Pharmaceuticals (JAZZ) to $225

On April 19, 2026, Barclays expert Etzer Darout raised the terms people connected Jazz Pharmaceuticals plc (NASDAQ:JAZZ) to $225 from $224 and maintained an Overweight standing connected the shares arsenic portion of a Q1 preview crossed the tiny and mid-cap biotechnology group.

Earlier successful April, Raymond James resumed sum of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) with an Outperform standing and a $227 terms target, saying the communicative has moved beyond the “it looks inexpensive/fairly valued, but wherever tin I get upside?” view, citing improved visibility into the process worth of the Epidiolex franchise and “highly competitive” information from zanidatamab successful gastroesophageal adenocarcinoma.

Last month, Piper Sandler raised its terms people connected Jazz Pharmaceuticals plc (NASDAQ:JAZZ) to $232 from $219 and maintained an Overweight rating, noting the institution trades astatine astir 7 times EV/2026E EBITDA portion offering visibility into double-digit top-line maturation starting successful 2027. The steadfast added that portion contention astir the oxybate franchise remains a factor, it does not expect it to materially impact the company’s wide maturation outlook.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) develops and commercializes pharmaceutical products crossed the United States, Europe, and planetary markets.

While we admit the imaginable of JAZZ arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey connected Google News.